{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:23Z","timestamp":1792723103576,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01090","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:21:27Z","timestamp":1791228087000},"page":"e01090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MuSK agonistic antibody has therapeutic potential for MuSK antibody-positive myasthenia gravis"],"prefix":"10.1016","volume":"23","author":[{"given":"Kentaro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genta","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Ogaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kunikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosumi","family":"Takaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01090_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.610964","article-title":"The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis","volume":"13","author":"Rodriguez Cruz","year":"2020","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01090_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01090_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2026.e01090_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01090_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.neurot.2026.e01090_bib7","doi-asserted-by":"crossref","first-page":"40624","DOI":"10.1074\/jbc.M111.279307","article-title":"Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK)","volume":"286","author":"Zhang","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"issue":"23","key":"10.1016\/j.neurot.2026.e01090_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300453120","article-title":"Structural insights into the assembly of the agrin\/LRP4\/MuSK signaling complex","volume":"120","author":"Xie","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01090_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1101\/gad.180885.111","article-title":"Structural basis of agrin-LRP4-MuSK signaling","volume":"26","author":"Zong","year":"2012","journal-title":"Genes Dev"},{"issue":"51","key":"10.1016\/j.neurot.2026.e01090_bib11","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2026.e01090_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnana.2016.00006","article-title":"Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy","volume":"10","author":"Boido","year":"2016","journal-title":"Front Neuroanat"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01090_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2020.07.031","article-title":"AAV9-DOK7 gene therapy reduces disease severity in Smn(2B\/-) SMA model mice","volume":"530","author":"Kaifer","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6203","key":"10.1016\/j.neurot.2026.e01090_bib14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.1250744","article-title":"Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction","volume":"345","author":"Arimura","year":"2014","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.neurot.2026.e01090_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158015","article-title":"Activation of muscle-specific kinase (MuSK) reduces neuromuscular defects in the Delta7 mouse model of spinal muscular atrophy (SMA)","volume":"22","author":"Feng","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01090_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19124072","article-title":"Neuromuscular junction changes in a mouse model of Charcot-Marie-Tooth disease type 4C","volume":"19","author":"Cipriani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01090_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.celrep.2012.08.004","article-title":"Increasing MuSK activity delays denervation and improves motor function in ALS mice","volume":"2","author":"Perez-Garcia","year":"2012","journal-title":"Cell Rep"},{"issue":"7867","key":"10.1016\/j.neurot.2026.e01090_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-021-03672-3","article-title":"Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia","volume":"595","author":"Oury","year":"2021","journal-title":"Nature"},{"issue":"765","key":"10.1016\/j.neurot.2026.e01090_bib19","doi-asserted-by":"crossref","first-page":"eado7189","DOI":"10.1126\/scitranslmed.ado7189","article-title":"ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome","volume":"16","author":"Vanhauwaert","year":"2024","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111684","article-title":"Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models","volume":"28","author":"Lim","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.neurot.2026.e01090_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34375","article-title":"Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody","volume":"7","author":"Cantor","year":"2018","journal-title":"eLife"},{"issue":"39","key":"10.1016\/j.neurot.2026.e01090_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408324121","article-title":"Agonist antibody to MuSK protects mice from MuSK myasthenia gravis","volume":"121","author":"Oury","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01090_bib23","doi-asserted-by":"crossref","first-page":"fcag115","DOI":"10.1093\/braincomms\/fcag115","article-title":"Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes","volume":"8","author":"Ho","year":"2026","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2026.e01090_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/3552793","article-title":"Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals","volume":"2022","author":"Fukuchi","year":"2022","journal-title":"Journal of Oncology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01090_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymeth.2005.01.004","article-title":"Use of human germline genes in a CDR homology-based approach to antibody humanization","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01090_bib25","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.4049\/jimmunol.147.8.2657","article-title":"Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG","volume":"147","author":"Lund","year":"1991","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01090_bib26","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1038\/s41598-023-32641-1","article-title":"Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK","volume":"13","author":"Lim","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp Neurol"},{"issue":"13","key":"10.1016\/j.neurot.2026.e01090_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020635118","article-title":"Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis","volume":"118","author":"Vergoossen","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2026.e01090_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-6606-5-7","article-title":"Wnt proteins regulate acetylcholine receptor clustering in muscle cells","volume":"5","author":"Zhang","year":"2012","journal-title":"Mol Brain"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01090_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","article-title":"Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human","volume":"5","author":"Shah","year":"2013","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01090_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2085535","article-title":"Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies","volume":"14","author":"Rafidi","year":"2022","journal-title":"mAbs"},{"issue":"17","key":"10.1016\/j.neurot.2026.e01090_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179142","article-title":"Laboratory investigation of hybrid IgG4 k\/lambda in MuSK positive myasthenia gravis","volume":"22","author":"Basile","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01090_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2026.e01090_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01090_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200513","article-title":"Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis","volume":"217","author":"Fichtner","year":"2020","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01090_bib37","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200147","article-title":"IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01090_bib38","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01090_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01090_bib40","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01090_bib41","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e01090_bib42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/NDT.S358851","article-title":"Efficacy and safety of low-dose rituximab in Anti-MuSK myasthenia gravis patients: a retrospective study","volume":"18","author":"Meng","year":"2022","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01090_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e01090_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e01090_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e01090_bib46","article-title":"A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01090_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101966","article-title":"Neuromuscular junction transmission failure in aging and sarcopenia: the nexus of the neurological and muscular systems","volume":"89","author":"Arnold","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"41","key":"10.1016\/j.neurot.2026.e01090_bib48","doi-asserted-by":"crossref","first-page":"8860","DOI":"10.1523\/JNEUROSCI.0860-18.2018","article-title":"Sarcoglycan alpha mitigates neuromuscular junction decline in aged mice by stabilizing LRP4","volume":"38","author":"Zhao","year":"2018","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01090_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101385","article-title":"DOK7 gene therapy enhances neuromuscular junction innervation and motor function in aged mice","volume":"23","author":"Ueta","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.neurot.2026.e01090_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834342","article-title":"IgG4 autoantibodies in organ-specific autoimmunopathies: reviewing class switching, antibody-producing cells, and specific immunotherapies","volume":"13","author":"Koneczny","year":"2022","journal-title":"Front Immunol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:55:22Z","timestamp":1792720522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002606"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01090","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MuSK agonistic antibody has therapeutic potential for MuSK antibody-positive myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01090"}}